Glaxo Smith Kline results, Fiscal year 2021
Net profit, assets, equity and cash flow for Fiscal year 2021, against the same period a year earlier, from the published financial statements.
Net profit155 millionEGP
Total assets2.42 billionEGP
Shareholders' equity1.36 billionEGP
Operating cash flow192 millionEGP
In short
- Glaxo Smith Kline's net profit for Fiscal year 2021 was about 155 million EGP.
- Total assets at the end of Fiscal year 2021 were about 2.42 billion EGP, and shareholders' equity about 1.36 billion EGP.
- Operating cash flow for Fiscal year 2021 was positive at 192 million EGP.
Key lines against the same period a year earlier
This periodYear earlierChange
Net profit155 million——
Gross profit759 million——
Total assets2.42 billion——
Total liabilities1.07 billion——
Shareholders' equity1.36 billion——
Total liabilities and equity2.42 billion——
Operating cash flow192 million——
Investing cash flow-35.15 million——
Financing cash flow-63.23 million——
Net change in cash51.41 million——
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version.
Glaxo Smith Kline's Q3 2026 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy